Dr. Christopher C. Case, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
1241 W Stadium Blvd
Jefferson City, MO 65109
Who else practices at this address →
Cole County is a federal primary care and dental shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Saint Louis University School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,140
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Saint Louis University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
MO license 112853 -
Internal Medicine Physician
MO license 112853
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Missouri Health Care Columbia, MO
- Boone Hospital Center Columbia, MO
- Lake Regional Health System Osage Beach, MO
- Phelps County Regional Medical Center Rolla, MO
- Ssm Health St. Mary's Hospital - Jefferson City Jefferson City, MO
Medical groups
- Jefferson City Medical Group PC (119 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,140
- Services billed
- 5,540
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 1,116 | 546 |
| Insertion of needle into vein for collection of blood sample | 705 | 388 |
| Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | 548 | 548 |
| Hemoglobin a1c level | 519 | 267 |
| Blood test, thyroid stimulating hormone (tsh) | 380 | 235 |
| Blood test, basic group of blood chemicals (calcium, total) | 330 | 238 |
| Blood test, lipids (cholesterol and triglycerides) | 285 | 179 |
| Blood test, comprehensive group of blood chemicals | 257 | 220 |
| Thyroxine (thyroid chemical), free | 214 | 145 |
| Interpretation of trabecular bone score (tbs) and report on fracture risk | 184 | 184 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Jefferson City, MO | 1,133 |
| Glimepiride Other prescribers in Jefferson City, MO | 963 |
| Metformin Hcl Other prescribers in Jefferson City, MO | 743 |
| Ozempic (semaglutide) Other prescribers in Jefferson City, MO | 724 |
| Pioglitazone Hcl Other prescribers in Jefferson City, MO | 664 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Jefferson City, MO | 446 |
| Mounjaro (tirzepatide) Other prescribers in Jefferson City, MO | 433 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Jefferson City, MO | 428 |
| Tresiba Flextouch U-200 (insulin degludec) Other prescribers in Jefferson City, MO | 345 |
| Humalog Kwikpen U-100 (insulin lispro) Other prescribers in Jefferson City, MO | 335 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 42 payments worth $8,590 in total to this clinician.
| Novo Nordisk Inc | $8,354 |
|---|---|
| Xeris Pharmaceuticals, Inc. | $53.40 |
| Corcept Therapeutics | $37.31 |
| Pfizer Inc. | $28.66 |
| Medtronic, Inc. | $26.36 |
| Radius Health, Inc. | $19.02 |
| Abbott Laboratories | $18.50 |
| Tolmar, Inc. | $18.29 |
| Compensation for services other than consulting (speaking, faculty) | $5,255 |
|---|---|
| Consulting Fee | $2,790 |
| Food and Beverage | $514 |
| Education | $32.27 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,668 |
| Novo Nordisk Inc Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,093 |
| Novo Nordisk Inc Sep 29, 2025 | Consulting Fee | $1,395 |
| Novo Nordisk Inc Sep 30, 2025 | Consulting Fee | $1,395 |
| Novo Nordisk Inc Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $494 |
| Novo Nordisk Inc Sep 23, 2025 | Education Wegovy · Obesity · in-kind | $32.27 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $293,751 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.